Exclusion Criteria:~* Current serious or unstable illnesses including cardiovascular, hepatic, renal,
gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or
hematologic disease and other conditions that, in the investigator's opinion, could interfere with outcome
assessments or the analyses in this study.~* Have received treatment with a passive anti-amyloid immunotherapy
after completion of originating donanemab study or received active immunization against AÎ² in any other
study.~* Poor venous access~* Contraindication to PET or MRI imaging
